Bertis secures $2M government grant for AI drug-target platform
Summary
Bertis has secured a $2.23 million government grant to develop an AI drug-target platform, aimed at advancing its capabilities in proteomics. This funding is part of a broader initiative by South Korea's Ministry of SMEs and Startups, which supports research and development in artificial intelligence and biotechnology to foster innovation among companies in these fields. Additionally, Bertis has been enhancing its platform through partnerships for the clinical validation of treatment targets, further demonstrating its commitment to advancing healthcare solutions.
Analysis
Bertis: Bertis is a South Korean proteomics technology company focused on AI-driven platforms for early cancer diagnostics and drug target discovery in precision medicine. It recently unveiled its SURF platform, which integrates experimental proteomics data with AI analysis and validation to identify therapeutic targets on cancer cell surfaces. The company is advancing collaborations for joint research and technology transfer with pharmaceutical partners based on this platform. Government Support: South Korea's Ministry of SMEs and Startups runs specialized programs to fund R&D in AI and biotechnology for innovative companies. Platform Advancement: Bertis continues to expand its proteomics capabilities through partnerships, including recent agreements for clinical validation of treatment targets.
Categories
aimachine_learningtech
Related sources
- https://www.cbinsights.com/company/bertis
- https://biz.heraldcorp.com/article/10829869
- https://app.dealroom.co/news/note/bertis-lands-2-23m-government-grant-to-build-ai-drug-target-platform
- https://www.bertis.com/
- https://simpler.grants.gov/opportunity/a3c4d6ca-08b3-44e1-a334-9f15d7605031
- https://science.osti.gov/ber/Funding-Opportunities
- https://noah-news.com/bertis-unveils-ai-driven-drug-target-platform-at-msd-health-innovation-summit/
- https://kr.linkedin.com/company/bertis-inc
- https://www.genomeweb.com/cancer/vanderbilt-health-bertis-collaborating-cancer-drug-target-biomarker-discovery